Abstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Although the overall incidence of CRC is decreasing, the incidence of young-onset CRC, characterized by a diagnosis of CRC before age 50, is increasing. Outcomes for CRC patients are improving, partly due to comprehensive molecular characterization of tumors and novel therapeutic strategies. Advances in genomic and transcriptomic analyses using blood- and tumor-tissue-based sequencing have facilitated identification of distinct tumor subtypes harboring unique biological characteristics and therapeutic vulnerabilities. These insights have led to the development and incorporation of targeted therapies and immunotherapy in CRC treatment. In this review, we discuss the molecular landscape and key oncogenes/tumor suppressors contributing to CRC tumorigenesis, metastasis, and therapeutic resistance. We also discuss personalized therapeutic strategies for subsets of CRC patients and provide an overview of evolving novel treatments being evaluated in clinical trials.
| Original language | American English |
|---|---|
| Article number | 1551 |
| Journal | Cancers |
| Volume | 16 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 2024 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Keywords
- colorectal cancer
- immunotherapy
- next generation sequencing
- targeted therapy
- young-onset colorectal cancer